1Mirabello L,Troisi RJ,Savage SA.Osteosarcoma incidence and survival rates from 1973 to 2004:data from the Surveillance,Epidemiology,and End Results Program[J].Cancer,2009,115(7):1531-1543.
2Mialou V,Philip T,Kalifa C,et al.Metastatic osteosarcoma at diagnosis,prognostic factors and long-term outcome:the French pediatric experience[J].Cancer,2005,104(5):1100-1109.
3Mankin HJ,Hornicek FJ,Rosenherg AE,et al.Survival data for 648 patients with osteosarcoma treated at one institution[J].Clin Orthop Relat Res,2004,420:286-291.
4Kurzman ID,Shi F,Vail DM,et al.In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells[J].Cancer Biother Radiopharm,1999,14(2):121-128.
5Ni J,Miller M,Stojanovic A,et al.Sustained effector function of IL-12/15/18 preactivated NK cells against established tumors[J].J Exp Med,2012,209(13):2351-2365.
6Lin YM,Chang ZL,Liao YY,et al.IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma[J].Cancer Lett,2013,328(1):135-143.
7Wang W,Song H,Liu J,et al.CD86+1057G/A polymorphism and susceptibility to osteosarcoma[J].DNA Cell Biol,2011,30(11):925-929.
8Suminoe A,Matsuzaki A,Hattori H,et al.Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors[J].Pediatr Transplant,2009,13(6):746-753.
3Huber BE, Austin EA, Cood SS, et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modfied to express cytosine dearninase. Cancer Research, 1993, 53(19) : 4619-4626.
4Li S, Yu B, An P, et al. Combined liposome-mediated cytosine deaminase gene therapy with radiation in killing rectal cancer cells and xenografts in athymic mice. Clin Cancer Res, 2005, 11(9) :3574-3578.
5Stefani AL, Barzon L, Castagliuolo I, et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J Hepatol, 2005, 42(5) :728-735.
6Chevez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by gancielovir. J Clin Oncol, 2005, 23(31):7927-7935.
7Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet, 1997, 349 (9044): 2-3.
8Rogalla P, Drechsler K, Kazmierczak Bet al. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade [J]. Mol Carcinog, 1997; 19(3):153- 156.
9Meyer B, Loeschke S, Schultze A et al. HMGA2 over expression in nonsmall cell lung cancer[J]. Mol Carcinog, 2007 ; 46 (7) : 503-511.
10Abe N, Watanabe T, Suzuki Yet al. An increased high mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue[ J]. Br J Cancer, 2003 ; 89( 11 ) : 2104-2109.
7Wang B,Feng D,Han L,et al.Combination of apolipoprotein A1-Modi Liposome-Doxorubicin with autophagy inhibitors overcame drug resistance in vitro. Journal of Pharmacological Sciences . 2014
8Ferrari S,Meazza C,Palmerini E,et al.Nonmetastatic osteosarcoma of the extremity.Neoadjuvant chemotherapy with methotrexate,cisplatin,doxorubicin and ifosfamide.An Italian Sarcoma Group study (ISG/OS-Oss). TUMORI . 2014
9Endo-Munoz L, Evdokiou A, Saunders NA. The role of osteo-clasts and turnout-associated macrophages in osteosarcoma me- tastasis[J]. Biochim Biophys Acta, 2012, 1826(2) :434-442.
10Lutetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment- Where do we stand? A state of the art review[J]. Cancer Treat Rev, 2014, 40(4):523-532.
